This excerpt taken from the SHPGY 8-K filed Mar 19, 2007. Registered in England 2883758 Registered Office as above Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
These excerpts taken from the SHPGY 8-K filed Mar 7, 2007. Registered in England 2883758 Registered Office as above Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
Registered in England 2883758 Registered Office as above Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
These excerpts taken from the SHPGY 8-K filed Mar 5, 2007. Registered in England 2883758 Registered Office as above believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
Registered in England 2883758 Registered Office as above Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
Registered in England 2883758 Registered Office as above attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
These excerpts taken from the SHPGY 8-K filed Mar 1, 2007. Registered in England 2883758 Registered Office as above Shires strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
Registered in England 2883758 Registered Office as above
The PSP awards will normally vest after three years, subject to any performance targets. Once vested, sufficient ordinary shares or ADRs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of PSP awards.
T May Registered in England 2883758 Registered Office as above attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com. Registered in England 2883758 Registered Office as above
FMR Corp is the parent holding company of Fidelity Management and Research Company (FMRCO), investment manager for US mutual funds and Fidelity Management Trust Company (FMTC), a US state chartered bank which acts as trustee or investment manager of various pension and trust accounts. Registered in England 2883758 Registered Office as above Proxy Voting:
Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276 Registered in England 2883758 Registered Office as above
Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276 Registered in England 2883758 Registered Office as above Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com. These excerpts taken from the SHPGY 8-K filed Feb 23, 2007. Registered in England 2883758 Registered Office as above believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
Registered in England 2883758 Registered Office as above believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire,
please visit the Companys website:
Registered in England 2883758 Registered Office as above Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com. These excerpts taken from the SHPGY 8-K filed Feb 15, 2007. Registered in England 2883758 Registered Office as above target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
Registered in England 2883758 Registered Office as above A replay of the presentation will be available for two weeks. Details are as follows:
This excerpt taken from the SHPGY 8-K filed Jan 24, 2007. Registered in England 2883758 Registered Office as above with the Securities and Exchange Commission, particularly Shire plcs Annual Report on Form 10-K for the year ended December 31, 2005.
This excerpt taken from the SHPGY 8-K filed Jan 19, 2007. believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
This excerpt taken from the SHPGY 8-K filed Jan 17, 2007. Giuliani S.p.A., founded in 1889, is a privately owned specialty pharmaceutical company with Headquarters in Milan, Italy. It develops new products with high unmet medical need and substantial market opportunity. It is focused on developing and marketing products for the treatment and management of gastrointestinal (ulcerative colitis and Crohn's disease), metabolic (food intolerance) and dermatological (hair loss) disorders. This excerpt taken from the SHPGY 8-K filed Jan 11, 2007. Registered in England 2883758 Registered Office as above
This excerpt taken from the SHPGY 8-K filed Dec 27, 2006. Registered in England 2883758 Registered Office as above ability to achieve certain threshold sales targets; our estimates regarding our capital requirements and our needs for additional financing; the likelihood of obtaining favorable scheduling and labeling of our drug products; the likelihood of regulatory approval under the Federal Food, Drug, and Cosmetic Act without having to conduct long and costly trials to generate all of the data which are often required in connection with a traditional new chemical entity; our ability to develop safer and improved versions of widely prescribed drugs using our Carrierwave (TM) technology; our success in developing our own sales and marketing capabilities for our lead product candidate, NRP104; and our ability to obtain favorable patent claims. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. New River Pharmaceuticals does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in New River Pharmaceuticals annual report on Form 10-K, filed with the SEC on March 15, 2006, as well as other public filings with the SEC.
This excerpt taken from the SHPGY 8-K filed Dec 21, 2006. Registered in England 2883758 Registered Office as above target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results. Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
This excerpt taken from the SHPGY 8-K filed Dec 15, 2006. Registered in England 2883758 Registered Office as above Shires focused strategy is to develop and market products for specialty physicians. Shires in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. For further information on Shire, please visit the Companys website: www.shire.com.
This excerpt taken from the SHPGY 8-K filed Dec 14, 2006. Registered in England 2883758 Registered Office as above SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD), MESAVANCE (mesalamine) with MMX technology (SPD476) (ulcerative colitis), ELAPRASE (idursulfase) (Hunter Syndrome) and NRP104 (lisdexamfetamine dimesylate) (ADHD), including its scheduling classification by the Drug Enforcement Administration in the United States; Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plcs Annual Report on Form 10-K for the year ended December 31, 2005.
This excerpt taken from the SHPGY 8-K filed Dec 14, 2006. Registered in England 2883758 Registered Office as above dimesylate) (ADHD), including its scheduling classification by the Drug Enforcement Administration in the United States; Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire's and its predecessor registrant Shire Pharmaceuticals Group plc's filings with the Securities and Exchange Commission, particularly Shire plcs Annual Report on Form 10-K for the year ended December 31, 2005. |